Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
grade C 0.945 3.86% 0.04
ALIM closed up 3.86 percent on Monday, May 20, 2019, on approximately normal volume.

Earnings due: May 23

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ALIM trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish 3.86%
Earnings Movers Other 3.86%
Fell Below 20 DMA Bearish 6.50%
180 Bearish Setup Bearish Swing Setup 6.50%
Earnings Movers Other 6.50%
Crossed Above 20 DMA Bullish 0.64%
20 DMA Resistance Bearish 3.28%

Older signals for ALIM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Medicine Chemistry Biopharmaceutical Diseases Organ Systems Disease Diabetes Age Related Macular Degeneration Blindness Fluid Dynamics Glucocorticoids Macular Edema Diabetic Retinopathy Diabetic Macular Edema Retina Pregnanes Alimera Sciences Diketones Retinal Vein Occlusion
Is ALIM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.21
52 Week Low 0.718
Average Volume 99,674
200-Day Moving Average 0.9876
50-Day Moving Average 1.0053
20-Day Moving Average 0.9321
10-Day Moving Average 0.9285
Average True Range 0.0545
ADX 14.25
+DI 16.9856
-DI 13.8532
Chandelier Exit (Long, 3 ATRs ) 0.8565
Chandelier Exit (Short, 3 ATRs ) 1.0135
Upper Bollinger Band 0.9929
Lower Bollinger Band 0.8713
Percent B (%b) 0.61
BandWidth 13.045811
MACD Line -0.0203
MACD Signal Line -0.0233
MACD Histogram 0.003
Fundamentals Value
Market Cap 65.25 Million
Num Shares 69 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -2.42
Price-to-Sales 2.38
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.09
Resistance 3 (R3) 1.08 1.03 1.07
Resistance 2 (R2) 1.03 0.99 1.03 1.06
Resistance 1 (R1) 0.99 0.97 1.01 0.99 1.05
Pivot Point 0.93 0.93 0.94 0.93 0.93
Support 1 (S1) 0.89 0.89 0.91 0.90 0.84
Support 2 (S2) 0.83 0.87 0.84 0.83
Support 3 (S3) 0.79 0.83 0.82
Support 4 (S4) 0.80